Skip to main content
. Author manuscript; available in PMC: 2015 May 1.
Published in final edited form as: Mol Cancer Ther. 2014 Feb 21;13(5):1044–1053. doi: 10.1158/1535-7163.MCT-13-0550

Figure 3. The combination AEB071/BYL719 synergistically reduces tumor cell viability in GNAQ mutant cells due to cooperative inhibition of PKC/ERK and PI3kα/AKT pathways.

Figure 3

Cells were treated with indicated AEB071/BYL719 concentrations for 2, 6 and 24 hrs and Western blots were then performed. Suppression of PKC/ERK and PI3Kα/AKT pathways was observed with the combination treatment in the GNAQ mutant cells, as evidenced by inhibition of MARCKS, ERK, AKT (Ser473) and S6 phosphorylation. α-Tubulin was used as a loading control.